Innovation Pharmaceuticals Inc (IPIX)

[Amatuer17]

JnJ has enormous cash and they can buy practically most of the medium pharma or any pharma with $70-80 B market cap.

Such buyout will give them new revenue streams and fast. K has not proven anything - with short half life they are talking about oral formulation which is another unknown. So K is at least 4+ years away from being on market - assuming it shows efficacy which is unknown.

So why they will spend time and money on such unknown drug than going after some proven moa such as PD-1 and move faster.

So my question is - why JnJ will go after K out of all promising cancer compounds? There is absolutely no connection between the 2.